Modified-release oral dosage forms are designed to control the timing, rate, or anatomical location of drug liberation, but control of release does not automatically confer equivalent control of systemic exposure. The relationship becomes conditional when formulation behavior interacts with food, gastrointestinal transit, luminal pH and fluid dynamics, regional absorptive capacity, dosage-form integrity, presystemic disposition, and patient-specific physiology. This Perspective examines those interactions by separating mechanisms that are often compressed into the single category of “modified release.” Hydrophilic matrices, osmotic systems, enteric or delayed-release constructs, and multiparticulate formulations possess different dependencies and therefore different failure signatures. Food may alter exposure through several simultaneous processes, including gastric residence, luminal composition, bile-mediated solubilization, intestinal fluid redistribution, regional delivery, and metabolic or transporter effects. Exposure may also diverge from intended release when a formulation reaches intestinal regions with lower effective absorptive capacity, when release is altered by an administration vehicle or alcohol-containing medium, or when aging, gastrointestinal surgery, comorbidity, interacting medicines, or within-subject physiological variation changes the absorption environment. These observations support a mechanism-sensitive interpretation of modified-release performance in which exposure predictability must be demonstrated for the relevant combination of dosage-form behavior, physiological state, and patient context. Biopredictive dissolution, physiologically based biopharmaceutics modeling, and virtual bioequivalence can help discriminate competing explanations when their assumptions and validation ranges are explicit. Predictable exposure is therefore an evidence-supported property of a product under defined conditions rather than an intrinsic consequence of assigning a modified-release mechanism.
